Download Research and development agreement for molecular targets in

Dealdoc
Research and development agreement for molecular targets in suppression of immune response in cancer
using Retrocyte Display technology platform (expanded)
4-Antibody
Ludwig Institute for Cancer Research
Recepta Biopharma
May 24 2011
© 2009-2017, Wildwood Ventures Ltd. All rights reserved.
Research and development agreement for molecular targets in suppression of immune response
in cancer using Retrocyte Display technology platform (expanded)
Companies:
Announcement date:
Deal value, US$m:
•
Details
•
Financials
•
Termsheet
•
Press Release
•
Filing Data
•
Contract
4-Antibody
Ludwig Institute for Cancer Research
Recepta Biopharma
May 24 2011
n/d
Details
Announcement date:
Industry sectors:
Therapy areas:
Technology types:
Deal components:
Stages of development:
May 24 2011
Biotech
Academic
Oncology
Antibodies » Monoclonal antibodies » Human mAb
Biological compounds
Clinical testing
Discovery tools
Development
Research
Discovery
Geographic focus:
North America » United States
South America » Brazil
Deal value, US$m:
n/d
Financials
Termsheet
29 January 2013
4-Antibody AG and the Ludwig Institute for Cancer Research announced the signing of a multi-target R&D collaboration with Recepta
Biopharma.
This represents an expansion of a partnership the Ludwig Institute and 4-Antibody initiated over a year ago.
Financial details were not disclosed.
The focus of the research and clinical development partnership will be the generation and development of three antibody products targeting
immune checkpoints important in cancer therapy.
The Ludwig Institute will validate the new constructs and then, together with Recepta Biopharma, take these antibody drugs into early clinical
testing in cancer in both the United States and Brazil, respectively.
Under the terms of the deal, 4-Antibody and Ludwig jointly own the antibody drugs while Recepta Biopharma obtains exclusive commercial rights
to Brazil in return for undisclosed licensing fees.
© 2009-2017, Wildwood Ventures Ltd. All rights reserved.
Future returns from the collaboration outside of Brazil will be shared among the three parties.
24 May 2011
Multi-target research alliance with the Ludwig Institute for Cancer Research (LICR).
Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of molecular targets which are
important in the suppression of the immune response in cancer.
Financial details were not disclosed.
Press Release
29 January 2013
4-Antibody AG and the Ludwig Institute for Cancer Research (the Ludwig Institute) today announced the signing of a multi-target R&D
collaboration with Recepta Biopharma SA, the leading Brazilian developer of therapeutic antibodies founded by the Ludwig Institute and
Brazilian investors. This represents an expansion of a partnership the Ludwig Institute and 4-Antibody initiated over a year ago. Financial details
were not disclosed.
The focus of the research and clinical development partnership will be the generation and development of three antibody products targeting
immune checkpoints important in cancer therapy. 4-Antibody will use its high-throughput Retrocyte Display® technology platform to generate
and produce fully human therapeutic antibodies against three targets with key roles in the suppression of immune responses in patients with
cancer. The parties anticipate the first candidate to enter clinical trials in early 2015. The Ludwig Institute will validate the new constructs and
then, together with Recepta Biopharma, take these antibody drugs into early clinical testing in cancer in both the United States and Brazil,
respectively.
Under the terms of the deal, 4-Antibody and Ludwig jointly own the antibody drugs while Recepta Biopharma obtains exclusive commercial rights
to Brazil in return for undisclosed licensing fees. 4-Antibody will take the lead securing commercialization partners for the antibody drugs in
territories outside Brazil on behalf of itself and Ludwig. Future returns from the collaboration outside of Brazil will be shared among the three
parties.
“We are expanding our pre-existing research and development alliance with the Ludwig Institute to include new clinically validated immune
checkpoint targets in this exciting and fast developing field in cancer immunotherapy. Our near-term goal is to generate early data which will
guide decisions on both optimum combination therapies as well as final product formats,” said Robert Burns, PhD, CEO of 4-Antibody.
“We have seen tremendous progress in the development of treatments that harness the power of the immune system to better detect and treat
cancer. This expanded collaboration will enable us to identify and evaluate new combinations of treatments to facilitate the development of the
next generation of more potent immunotherapy drugs,” concluded Jonathan Skipper, PhD, the Ludwig Institute’s Executive Director of
Technology Development.
Fernando Perez, PhD, Recepta’s CEO, added, “Recepta is committed to developing and testing innovative antibody-based cancer treatments for
patients. This partnership expands our pipeline to include the development and testing of the next generation of immunomodulatory drugs,
further strengthening Recepta’s role in the Brazilian biotechnology health market”
24 May 2011
4-Antibody AG Forms Multi-target Oncology Research and Development Alliance with the Ludwig Institute For Cancer Research (LICR)
5/24/2011
Basel, Switzerland, 24th May, 2011: 4-Antibody AG today announced the signing of a multi-target research alliance with the Ludwig Institute for
Cancer Research (LICR). Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of
molecular targets which are important in the suppression of the immune response in cancer. Financial details were not disclosed.
4-Antibody will use its high throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibodies
against a series of disease targets with key roles in the suppression of immune responses in cancer patients. The Ludwig Institute will then take
these antibody drugs into early clinical testing with the specific clinical goal of demonstrating the feasibility of reversing immunosuppression in
cancer. At the point at which the programmes have achieved agreed technical milestones, 4-Antibody will seek pharmaceutical partnerships for
the emerging product opportunities.
Dr Robert Burns, CEO of 4-Antibody, commented:
“For nearly three decades the Ludwig Institute has focused its worldwide clinical research efforts in cancer immunology and has built an
extraordinary expertise in the monitoring of patient immunological responses in cancer immunotherapy settings. The concept of reversing
© 2009-2017, Wildwood Ventures Ltd. All rights reserved.
tolerance in cancer has been clinically validated with the recent approval of an anti-CTLA4 antibody. We intend to target parallel pathways in our
programme with LICR through its research branch at the Memorial Sloan Kettering Cancer Center in New York where we expect eventual
clinical trials to take place.”
Andrew Simpson, PhD, LICR’s Scientific Director, added:
“The Ludwig Institute has a long history of conducting innovative clinical research in the field of cancer immunotherapy. The combination of
4-Antibody’s high throughput Retrocyte Display® technology and its ability to rapidly generate panels of novel fully human full length therapeutic
antibodies will speed our research into the identification of clinical strategies to selective interfere with the immunomodulatory mechanisms that
lie at the heart of tumours’ ability to evade otherwise effective immune responses – a major goal for the improved treatment of cancer.”
About 4-Antibody AG
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an
emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in-vitro Retrocyte Display® technology, a fast and highly
efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a
rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells
(the cell designed by nature for optimal antibody display). This in vitro process is supported by the in vivo HU-PAC® filter used to select only
those antibody product candidates with the most desirable drug characteristics. 4-Antibody provides access to its technologies to select
pharmaceutical R&D collaborators and is also generating an in-house pipeline of antibody drugs. The Company’s lead development product is
an anti-cytomegalovirus antibody drug. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel,
Switzerland and Jena, Germany. For more information please visit: www.4-antibody.com
About LICR
The Ludwig Institute for Cancer Research Ltd is a non-profit research organization committed to improving the control of cancer through
integrated laboratory and clinical research and novel therapeutic strategies based on the emerging understanding of cancer. The Institute
translates these strategies into applications for human benefit by coupling discoveries from its basic laboratory research and renowned scientists
with strong intellectual property positions, clinical development expertise and the conduct of Institute-sponsored, GCP compliant clinical trials.
The core of the Institute is concentrated at ten research locations two each in Australia, Sweden and the USA, and one each in Belgium, Brazil,
Switzerland and the UK. Each research site is led by a Director who is a Member scientist of the Institute and part of the management team.
Filing Data
Not available.
Contract
Not available.
© 2009-2017, Wildwood Ventures Ltd. All rights reserved.